Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study.
POMME cohort
child
delayed effects
medication
neuropsychiatric disorders
pharmacoepidemiology
prenatal exposure
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
10
2021
accepted:
15
02
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Neuropsychiatric disorders in childhood after prenatal drug exposure raises concerns. Most of the published studies focused on psychotropic medications. This study investigated which prenatal medication exposure was associated with neuropsychiatric disorders in childhood. A case-control study, nested in the French POMME cohort, was conducted to compare prenatal medication exposure between children with a history of neuropsychiatric care (ages 0-8 years) and children in a control group. POMME included children born in Haute-Garonne to women covered by the general Health Insurance System, between 2010 and 2011 ( A total of 723 (8.6%) cases and 4,924 (58.8%) controls were identified. This study showed a statistically significant difference in prenatal exposure to nervous system drugs (excluding analgesics) between the groups [ORa: 2.12 (1.55; 2.90)]. Differences (not statistically significant at the 0.0033 threshold) were also observed for the ATC classes: Musculoskeletal, Genito-urinary System and Sex Hormones, Alimentary Tract and Anti-infectives. Through identification of children with neuropsychiatric disorders and of their prenatal medication exposure, this study provides guidance for the assessment of long-term neuropsychiatric effects after prenatal medication exposure, without focusing on psychotropic medications.
Sections du résumé
Background and Objectives
UNASSIGNED
Neuropsychiatric disorders in childhood after prenatal drug exposure raises concerns. Most of the published studies focused on psychotropic medications. This study investigated which prenatal medication exposure was associated with neuropsychiatric disorders in childhood.
Methods
UNASSIGNED
A case-control study, nested in the French POMME cohort, was conducted to compare prenatal medication exposure between children with a history of neuropsychiatric care (ages 0-8 years) and children in a control group. POMME included children born in Haute-Garonne to women covered by the general Health Insurance System, between 2010 and 2011 (
Results
UNASSIGNED
A total of 723 (8.6%) cases and 4,924 (58.8%) controls were identified. This study showed a statistically significant difference in prenatal exposure to nervous system drugs (excluding analgesics) between the groups [ORa: 2.12 (1.55; 2.90)]. Differences (not statistically significant at the 0.0033 threshold) were also observed for the ATC classes: Musculoskeletal, Genito-urinary System and Sex Hormones, Alimentary Tract and Anti-infectives.
Conclusion
UNASSIGNED
Through identification of children with neuropsychiatric disorders and of their prenatal medication exposure, this study provides guidance for the assessment of long-term neuropsychiatric effects after prenatal medication exposure, without focusing on psychotropic medications.
Identifiants
pubmed: 35392389
doi: 10.3389/fpsyt.2022.795890
pmc: PMC8980541
doi:
Types de publication
Journal Article
Langues
eng
Pagination
795890Informations de copyright
Copyright © 2022 Benevent, Hurault-Delarue, Araujo, Revet, Sommet, Lacroix and Damase-Michel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Drug Saf. 2019 Jan;42(1):45-54
pubmed: 30121741
BMJ Open. 2020 Jun 7;10(6):e034829
pubmed: 32513880
Clin Pharmacol Ther. 2009 Dec;86(6):672-7
pubmed: 19890255
JAMA Netw Open. 2019 Apr 5;2(4):e191435
pubmed: 30951155
J Clin Psychiatry. 2014 Oct;75(10):1088-95
pubmed: 25373117
Public Health. 2015 Dec;129(12):1610-7
pubmed: 26318615
J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1575-83
pubmed: 15491979
J Clin Psychopharmacol. 2018 Aug;38(4):327-335
pubmed: 29851707
JAMA. 2017 Apr 18;317(15):1553-1562
pubmed: 28418479
Am J Psychiatry. 2012 Nov;169(11):1165-74
pubmed: 23128923
PLoS One. 2019 Aug 29;14(8):e0221921
pubmed: 31465485
Pediatr Res. 2019 Jan;85(2):113-114
pubmed: 30367161
Pharmacoepidemiol Drug Saf. 2019 Apr;28(4):452-459
pubmed: 30838712
Birth Defects Res C Embryo Today. 2016 Sep;108(3):207-223
pubmed: 27774781
Dev Med Child Neurol. 2017 Dec;59(12):1284-1290
pubmed: 28905997
Eur J Clin Pharmacol. 2015 Mar;71(3):283-91
pubmed: 25547568
BMJ. 1998 Apr 18;316(7139):1236-8
pubmed: 9553006
J Autism Dev Disord. 2019 Sep;49(9):3866-3876
pubmed: 31175505
J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):637-43
pubmed: 23370617
Pediatrics. 2010 Mar;125(3):e600-8
pubmed: 20176667
J Clin Psychiatry. 2016 Apr;77(4):e411-4
pubmed: 27137425
BMJ. 2017 May 31;357:j2350
pubmed: 28566274
Epilepsia. 2013 Aug;54(8):1462-72
pubmed: 23865818
Arthritis Care Res (Hoboken). 2013 May;65(5):759-66
pubmed: 23139238
Res Dev Disabil. 2011 Nov-Dec;32(6):2704-13
pubmed: 21705192
Eur Child Adolesc Psychiatry. 2015 Feb;24(2):173-83
pubmed: 24796725
Br J Psychiatry. 2014 Aug;205(2):95-102
pubmed: 25252317
Epilepsy Behav. 2009 Jan;14(1):197-201
pubmed: 18992367
Nutr Rev. 2018 Sep 1;76(9):708-721
pubmed: 30010929
Fundam Clin Pharmacol. 2022 Feb;36(1):16-34
pubmed: 33998708
PLoS One. 2017 Jul 26;12(7):e0181042
pubmed: 28746341
Neurotoxicol Teratol. 2017 May;61:58-65
pubmed: 28259732
J Clin Psychiatry. 2011 Jul;72(7):1002-7
pubmed: 21672498
Eur Child Adolesc Psychiatry. 2018 Sep;27(9):1209-1230
pubmed: 29948232
JAMA. 2013 Apr 24;309(16):1696-703
pubmed: 23613074
Pediatrics. 2017 Apr;139(Suppl 1):S23-S37
pubmed: 28562246
Seizure. 2017 Jan;44:225-231
pubmed: 27784632